Research Output per year
Research Output 2003 2019
- 1 - 50 out of 72 results
- Publication Year, Title (descending)
2019
1
Citation
(Scopus)
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Stein, M., Goodin, S., Gounder, M., Gibbon, D., Moss, R., Portal, D., Lindquist, D., Zhao, Y., Takebe, N., Tan, A., Aisner, J., Lin, H., Ready, N. & Mehnert, J., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.Research output: Contribution to journal › Article
Carboplatin
Paclitaxel
Neoplasms
Area Under Curve
Prostate
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
Mehnert, J., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J., Gibbon, D., Doyle, L. A., White, E. & Stein, M., Jan 1 2019, (Accepted/In press) In : Cancer chemotherapy and pharmacology.Research output: Contribution to journal › Article
Hydroxychloroquine
Tumors
Neoplasms
Exanthema
Fatigue
5
Citations
(Scopus)
Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial
Keilholz, U., Mehnert, J., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.Research output: Contribution to journal › Article
Melanoma
Neoplasms
Therapeutics
Disease-Free Survival
Survival
1
Citation
(Scopus)
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
Andtbacka, R. H. I., Amatruda, T., Nemunaitis, J., Zager, J. S., Walker, J., Chesney, J. A., Liu, K., Hsu, C. P., Pickett, C. A. & Mehnert, J., Sep 1 2019, In : EBioMedicine. 47, p. 89-97 9 p.Research output: Contribution to journal › Article
Open Access
Oncolytic Viruses
Viruses
Melanoma
Occlusive Dressings
Blood
Clinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 others, , Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.Research output: Contribution to journal › Article
Colitis
Steroids
Therapeutics
Prednisone
Melanoma
Cytokine Therapy
Silk, A. & Margolin, K., Apr 1 2019, In : Hematology/Oncology Clinics of North America. 33, 2, p. 261-274 14 p.Research output: Contribution to journal › Review article
Cytokines
Therapeutics
Neoplasms
Direction compound
4
Citations
(Scopus)
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
D’Angelo, S. P., Hunger, M., Brohl, A. S., Nghiem, P., Bhatia, S., Hamid, O., Mehnert, J., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Schlichting, M., Hennessy, M. H. & Bharmal, M., Apr 2 2019, In : Cancer Immunology, Immunotherapy. 68, 4, p. 609-618 10 p.Research output: Contribution to journal › Article
Merkel Cell Carcinoma
Survival
Confidence Intervals
Therapeutics
Proportional Hazards Models
1
Citation
(Scopus)
Erratum to: Autophagy maintains tumour growth through circulating arginine (Nature, (2018), 563, 7732, (569-573), 10.1038/s41586-018-0697-7)
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J., Guo, Y., Lattime, E., Rabinowitz, J. D. & White, E., Jan 3 2019, In : Nature. 565, 7737, p. E3Research output: Contribution to journal › Comment/debate
Autophagy
Arginine
Carcinogenesis
Growth
Neoplasms
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing
Boussemart, L., Nelson, A., Wong, M., Ross, J. S., Sosman, J., Mehnert, J., Daniels, G., Kendra, K., Ali, S. M., Miller, V. A. & Schrock, A. B., May 2019, In : Oncologist. 24, 5, p. 657-663 7 p.Research output: Contribution to journal › Review article
Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Practice Guidelines
Patient Selection
3
Citations
(Scopus)
Interferon Lambda: Toward a Dual Role in Cancer
Lasfar, A., Zloza, A., Silk, A., Lee, L. & Cohen-Solal, K. A., Jan 1 2019, In : Journal of Interferon and Cytokine Research. 39, 1, p. 22-29 8 p.Research output: Contribution to journal › Article
Interferons
Neoplasms
Inflammation
Janus Kinases
Transducers
Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
Chesney, J., Puzanov, I., Collichio, F., Milhem, M. M., Hauschild, A., Chen, L., Sharma, A., Garbe, C., Singh, P. & Mehnert, J., Aug 27 2019, In : British Journal of Cancer. 121, 5, p. 417-420 4 p.Research output: Contribution to journal › Article
Melanoma
Tumor Burden
ipilimumab
Therapeutics
11
Citations
(Scopus)
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
Varga, A., Piha-Paul, S., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Yang, P., Ruman, J. & Matei, D., Feb 2019, In : Gynecologic Oncology. 152, 2, p. 243-250 8 p.Research output: Contribution to journal › Article
Ovarian Neoplasms
Ligands
Therapeutics
Research Personnel
Safety
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma
Portal, D. E., Weiss, R. E., Wojtowicz, M., Mansour, A., Monken, C., Mehnert, J. M., Aisner, J. A., Kane, M., Nishioka, J., Aisner, S., Peters, S., Stein, M. N., Kim, I. Y., Mayer, T. M., Shih, W., Gulley, J., Streicher, H., Singer, E. A. & Lattime, E. C., Jan 1 2019, In : Cancer gene therapy.Research output: Contribution to journal › Article
Fowlpox
Granulocyte-Macrophage Colony-Stimulating Factor
Urinary Bladder
Urinary Bladder Neoplasms
Carcinoma
1
Citation
(Scopus)
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: A multicenter, retrospective case series
Lopiccolo, J., Schollenberger, M. D., Dakhil, S., Rosner, S., Ali, O., Sharfman, W. H., Silk, A. W., Bhatia, S. & Lipson, E. J., Jul 8 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 170.Research output: Contribution to journal › Article
Open Access
Merkel Cell Carcinoma
Therapeutics
Neoplasms
Blocking Antibodies
Multicenter Studies
4
Citations
(Scopus)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C. C., Prawira, A., De Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., Gilbert, J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Keam, B., Mar 4 2019, In : BMC cancer. 19, 1, 196.Research output: Contribution to journal › Article
Ligands
Safety
Antibodies
Thyroid Neoplasms
Confidence Intervals
39
Citations
(Scopus)
T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028
Ott, P. A., Bang, Y. J., Piha-Paul, S. A., Abdul Razak, A. R., Bennouna, J., Soria, J. C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J., Lopez, J., Doi, T., van Brummelen, E. M. J., Cristescu, R., Yang, P., Emancipator, K., Stein, K., Ayers, M., Joe, A. K. & Lunceford, J. K., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 318-327 10 p.Research output: Contribution to journal › Article
Tumor Burden
Transcriptome
Ligands
Neoplasms
Disease-Free Survival
3
Citations
(Scopus)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. & McDermott, D. F., Feb 18 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 49.Research output: Contribution to journal › Article
Open Access
Renal Cell Carcinoma
Interleukin-2
Melanoma
Therapeutics
Pneumonia
2018
13
Citations
(Scopus)
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L., Gajewski, T. F., Gastman, B., Lawson, D. H., Lutzky, J., McDermott, D. F., Margolin, K. A., Mehnert, J. M., Pavlick, A. C., Richards, J. M., Rubin, K. M., Sharfman, W., Silverstein, S., Slingluff, C. L. & 8 others, , May 30 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 44.Research output: Contribution to journal › Article
Immunotherapy
Melanoma
Consensus
Skin
Advisory Committees
2
Citations
(Scopus)
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Mehnert, J., Edelman, G., Stein, M., Camisa, H., Lager, J., Dedieu, J. F., Ghuysen, A. F., Sharma, J., Liu, L. & LoRusso, P. M., Feb 1 2018, In : Investigational New Drugs. 36, 1, p. 36-44 9 p.Research output: Contribution to journal › Article
1-Phosphatidylinositol 4-Kinase
Tablets
Pharmacokinetics
Safety
Neoplasms
4
Citations
(Scopus)
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma
Mehnert, J. M., Silk, A. W., Lee, J. H., Dudek, L., Jeong, B. S., Li, J., Schenkel, J. M., Sadimin, E., Kane, M., Lin, H., Shih, W. J., Zloza, A., Chen, S. & Goydos, J. S., Jul 2018, In : Pigment Cell and Melanoma Research. 31, 4, p. 534-540 7 p.Research output: Contribution to journal › Article
Riluzole
Tumors
Melanoma
Pharmacokinetics
Down-Regulation
38
Citations
(Scopus)
Autophagy maintains tumour growth through circulating arginine
Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J., Guo, Y., Lattime, E., Rabinowitz, J. D. & White, E., Nov 22 2018, In : Nature. 563, 7732, p. 569-573 5 p.Research output: Contribution to journal › Letter
Autophagy
Arginine
Growth
Neoplasms
Essential Genes
27
Citations
(Scopus)
Immune activation and benefit from avelumab in EBV-positive gastric cancer
Panda, A., Mehnert, J., Hirshfield, K., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M., Poplin, E., Rodriguez-Rodriguez, L., Silk, A., Aisner, J., Chan, N., Malhotra, J., Frankel, M., Kaufman, H. L., Ali, S., Ross, J. S., White, E. P. & 2 others, , Mar 1 2018, In : Journal of the National Cancer Institute. 110, 3, p. 316-320 5 p.Research output: Contribution to journal › Article
Human Herpesvirus 4
Stomach Neoplasms
Microsatellite Repeats
Neoplasms
Mutation
1
Citation
(Scopus)
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Hurwitz, M. E., Markowski, P., Yao, X., Deshpande, H., Patel, J., Mortazavi, A., Donadio, A., Stein, M., Kelly, W. K., Petrylak, D. P. & Mehnert, J., Dec 1 2018, In : Clinical Genitourinary Cancer. 16, 6, p. 437-444.e6Research output: Contribution to journal › Article
gemcitabine
Transitional Cell Carcinoma
Carboplatin
Confidence Intervals
Protein-Tyrosine Kinases
1
Citation
(Scopus)
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Ascierto, P. A., Puzanov, I., Agarwala, S. S., Bifulco, C., Botti, G., Caracò, C., Ciliberto, G., Davies, M. A., Dummer, R., Ferrone, S., Gajewski, T. F., Garbe, C., Luke, J. J., Marincola, F. M., Masucci, G., Mehnert, J. M., Mozzillo, N., Palmieri, G., Postow, M. A., Schoenberger, S. P. & 2 others, , Jul 21 2018, In : Journal of translational medicine. 16, 1, 207.Research output: Contribution to journal › Article
Italy
Tumors
Melanoma
Proto-Oncogene Proteins B-raf
T-cells
2
Citations
(Scopus)
Phase IB results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer
Krishnamurthy, A., Dasari, A., Noonan, A. M., Mehnert, J. M., Lockhart, A. C., Leong, S., Capasso, A., Stein, M. N., Sanoff, H. K., Lee, J. J., Hansen, A., Malhotra, U., Rippke, S., Gustafson, D. L., Pitts, T. M., Ellison, K., Davis, S. L., Messersmith, W. A., Eckhardt, S. G. & Lieu, C. H., Sep 15 2018, In : Cancer Research. 78, 18, p. 5398-5407 10 p.Research output: Contribution to journal › Article
Cyclosporine
Colorectal Neoplasms
Wnt Signaling Pathway
Neoplasms
oxaliplatin
10
Citations
(Scopus)
Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., Egan, J. O., Jones, M., Rhode, P. R., Rock, A. D., Cheever, M. A., Wong, H. C. & Ernstoff, M. S., Nov 15 2018, In : Clinical Cancer Research. 24, 22, p. 5552-5561 10 p.Research output: Contribution to journal › Article
Interleukin-15
Neoplasms
Natural Killer Cells
Melanoma
Lymphocytes
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study
Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M. & Soria, J. C., Jan 1 2018, In : Obstetrical and Gynecological Survey. 73, 1, p. 26-27 2 p.Research output: Contribution to journal › Comment/debate
Endometrial Neoplasms
Ligands
Safety
pembrolizumab
23
Citations
(Scopus)
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
Kelly, K., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., May 1 2018, In : Cancer. 124, 9, p. 2010-2017 8 p.Research output: Contribution to journal › Article
Clinical Trials
Safety
Neoplasms
avelumab
CD274 Antigen
2017
18
Citations
(Scopus)
BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAFV600E mutant melanoma
Kulkarni, A., Al-Hraishawi, H., Simhadri, S., Hirshfield, K. M., Chen, S., Pine, S., Jeyamohan, C., Sokol, L., Ali, S., Teo, M. L., White, E., Rodriguez-Rodriguez, L., Mehnert, J. M. & Ganesan, S., Sep 15 2017, In : Clinical Cancer Research. 23, 18, p. 5631-5638 8 p.Research output: Contribution to journal › Article
Melanoma
Gene Fusion
Mitogen-Activated Protein Kinase Kinases
Mutation
PLX4032
32
Citations
(Scopus)
First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors
Stein, M., Bertino, J., Kaufman, H. L., Mayer, T., Moss, R., Silk, A., Chan, N., Malhotra, J., Rodriguez-Rust, L., Aisner, J., Aiken, R., Haffty, B., DiPaola, R. S., Saunders, T., Zloza, A., Damare, S., Beckett, Y., Yu, B., Najmi, S., Gabel, C. & 7 others, , Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4163-4169 7 p.Research output: Contribution to journal › Article
Clinical Trials
Neoplasms
Pharmacokinetics
Keratin-18
Endometrial Neoplasms
15
Citations
(Scopus)
Immuno-oncology clinical trial design: Limitations, challenges, and opportunities
Baik, C. S., Rubin, E. H., Forde, P. M., Mehnert, J. M., Collyar, D., Butler, M. O., Dixon, E. L. & Chow, L. Q. M., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4992-5002 11 p.Research output: Contribution to journal › Article
Clinical Trials
Neoplasms
Therapeutics
Safety
Virus Diseases
14
Citations
(Scopus)
Intratumoral Approaches for the Treatment of Melanoma
Bommareddy, P. K., Silk, A. & Kaufman, H. L., Jan 1 2017, In : Cancer Journal (United States). 23, 1, p. 40-47 8 p.Research output: Contribution to journal › Review article
Melanoma
Neoplasms
Immunotherapy
Therapeutics
Oncolytic Viruses
241
Citations
(Scopus)
Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Nov 21 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 95.Research output: Contribution to journal › Article
Immunotherapy
Neoplasms
Therapeutic Uses
Therapeutics
Nervous System
20
Citations
(Scopus)
Oncolytic viruses-natural and genetically engineered cancer immunotherapies
Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W. & Zloza, A., Sep 11 2017, In : Frontiers in Oncology. 7, SEP, 202.Research output: Contribution to journal › Review article
Oncolytic Viruses
Immunotherapy
Neoplasms
Viruses
Therapeutics
123
Citations
(Scopus)
Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study
Ott, P. A., Elez, E., Hiret, S., Kim, D. W., Morosky, A., Saraf, S., Piperdi, B. & Mehnert, J., Dec 1 2017, In : Journal of Clinical Oncology. 35, 34, p. 3823-3829 7 p.Research output: Contribution to journal › Article
Small Cell Lung Carcinoma
Safety
Asthenia
Ligands
pembrolizumab
2
Citations
(Scopus)
Pseudoprogression of a spinal metastasis after stereotactic ablative body radiation therapy and immune checkpoint therapy
Jhawar, S. R., Silk, A. & Goyal, S., Mar 1 2017, In : Practical Radiation Oncology. 7, 2, p. 109-112 4 p.Research output: Contribution to journal › Article
Radiotherapy
Neoplasm Metastasis
Therapeutics
92
Citations
(Scopus)
Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study
Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M. & Soria, J. C., Aug 1 2017, In : Journal of Clinical Oncology. 35, 22, p. 2535-2541 7 p.Research output: Contribution to journal › Article
Endometrial Neoplasms
Ligands
Safety
pembrolizumab
Therapeutics
68
Citations
(Scopus)
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
Hsu, C., Lee, S. H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J., Algazi, A., Van Brummelen, E. M. J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Hansen, A. R., Dec 20 2017, In : Journal of Clinical Oncology. 35, 36, p. 4050-4056 7 p.Research output: Contribution to journal › Article
Ligands
Safety
Drug-Related Side Effects and Adverse Reactions
Nasopharyngeal carcinoma
pembrolizumab
24
Citations
(Scopus)
The challenge for development of valuable immuno-oncology biomarkers
Mehnert, J., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L. & Harris, L. N., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4970-4979 10 p.Research output: Contribution to journal › Article
Biomarkers
Tumor Microenvironment
Immunotherapy
Tumor-Infiltrating Lymphocytes
Tumor Burden
2016
14
Citations
(Scopus)
A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer
Stein, M. N., Hussain, M., Stadler, W. M., Liu, G., Tereshchenko, I. V., Goodin, S., Jeyamohan, C., Kaufman, H. L., Mehnert, J. & Dipaola, R. S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. 22-27 6 p.Research output: Contribution to journal › Article
Castration
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
22
Citations
(Scopus)
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A., Ganesan, S., Kaufman, H. L. & Mehnert, J., Jan 1 2016, In : American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 35, p. e493-e503Research output: Contribution to journal › Article
Immunotherapy
Biomarkers
Tumor Microenvironment
Neoplasms
Tumor-Infiltrating Lymphocytes
21
Citations
(Scopus)
Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers
Hirshfield, K., Tolkunov, D., Zhong, H., Ali, S. M., Stein, M., Murphy, S., Vig, H., Vazquez, A., Glod, J., Moss, R. A., Belyi, V., Chan, C., Chen, S., Goodell, L., Foran, D., Yelensky, R., Palma, N. A., Sun, J. X., Miller, V. A., Stephens, P. J. & 10 others, , Nov 1 2016, In : Oncologist. 21, 11, p. 1315-1325 11 p.Research output: Contribution to journal › Article
Neoplasms
Histology
Proto-Oncogene Proteins c-akt
Genetic Testing
Receptor Protein-Tyrosine Kinases
11
Citations
(Scopus)
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., Fu, Y. X., Gajewski, T. F., Garbe, C., Huber, V., Khleif, S., Krauthammer, M., Lo, R. S., Masucci, G., Palmieri, G., Postow, M. & 16 others, , Nov 15 2016, In : Journal of translational medicine. 14, 1, 313.Research output: Contribution to journal › Article
Biomarkers
Melanoma
Immunotherapy
Tumors
CTLA-4 Antigen
30
Citations
(Scopus)
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Schadendorf, D., Dummer, R., Hauschild, A., Robert, C., Hamid, O., Daud, A., van den Eertwegh, A., Cranmer, L., O'Day, S., Puzanov, I., Schachter, J., Blank, C., Salama, A., Loquai, C., Mehnert, J. M., Hille, D., Ebbinghaus, S., Kang, S. P., Zhou, W. & Ribas, A., Nov 1 2016, In : European Journal of Cancer. 67, p. 46-54 9 p.Research output: Contribution to journal › Article
Melanoma
Quality of Life
Drug Therapy
Health Status
ipilimumab
113
Citations
(Scopus)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M., Rodriguez-Rodriquez, L., Kaufman, H. L., Ali, S., Ross, J. S., Pavlick, D. C., Bhanot, G., White, E., DiPaola, R. S., Lovell, A., Cheng, J. & Ganesan, S., Jun 1 2016, In : Journal of Clinical Investigation. 126, 6, p. 2334-2340 7 p.Research output: Contribution to journal › Article
Endometrial Neoplasms
Mutation
Programmed Cell Death 1 Receptor
Neoplasms
DNA Polymerase II
2
Citations
(Scopus)
Importance of including patients with comorbidities in clinical trials
Spencer, K. R. & Mehnert, J., Jan 1 2016, In : The Lancet Oncology. 17, 1, p. 17-18 2 p.Research output: Contribution to journal › Comment/debate
Patient Selection
Comorbidity
Clinical Trials
83
Citations
(Scopus)
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
Rehman, H., Silk, A. W., Kane, M. P. & Kaufman, H. L., Sep 20 2016, In : Journal for ImmunoTherapy of Cancer. 4, 1, 53.Research output: Contribution to journal › Article
Melanoma
Oncolytic Viruses
Therapeutics
Drug Compounding
Explosions
220
Citations
(Scopus)
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J., Sosman, J. A., Long, G. V. & 1 others, , Feb 1 2016, In : JAMA Oncology. 2, 2, p. 234-240 7 p.Research output: Contribution to journal › Article
Preexisting Condition Coverage
Melanoma
Autoimmune Diseases
Therapeutics
Safety
27
Citations
(Scopus)
Mucosal melanoma: Epidemiology, biology and treatment
Spencer, K. R. & Mehnert, J., Jan 1 2016, Cancer Treatment and Research. Kluwer Academic Publishers, p. 295-320 26 p. (Cancer Treatment and Research; vol. 167).Research output: Chapter in Book/Report/Conference proceeding › Chapter
Melanoma
Epidemiology
Skin
Oncogenes
Therapeutics
2015
71
Citations
(Scopus)
Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma
Xie, X., Koh, J. Y., Price, S., White, E. & Mehnert, J. M., Apr 1 2015, In : Cancer Discovery. 5, 4, p. 410-423 14 p.Research output: Contribution to journal › Article
Autophagy
Melanoma
Growth
Essential Genes
Neoplasms